Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Beats Revenue Estimates
Syndax (SNDX) delivered earnings and revenue surprises of +17.00% and +30.74%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?